Italiano Farmacia on line: comprare cialis senza ricetta, acquistare viagra internet.

Ex sum/pdf_6_01_0

Pharmacotherapy of Dyslipidemia
KHOI NGUYEN LAM
Disease State
Definition
• Premature CAD • Typically with first degree relative Epidemiology - 65 million quality for lifestyle changes
- 1/67 Ashkenazi Jews - 1/100 Afrikaners, South African Indians - Susceptible genotype (no gene discovered) physiology
- Aggravated by excessive saturated fat, trans - Decreased LDL cellular uptake - Diet high in fat/cholesterol decrease LDL Clinical
Presentation
- Premature Coronary artery disease (CAD) o Abdominal obesity (♂ > 40”; ♀ > 35”) Risk Factors
o Cigarette Smoking o HTN (>140/90) o HDL (< 40) o Family Hx o Age (♂ > 45; ♀ > 55) Diagnosis
Therapeutic
Outcomes*
*Reference of
Guidelines
Used
(ATP 3)
Pharmacotherapy Presentation – Pharmaceutical Care Rotation University of Maryland School of Pharmacy Happy Harry’s Pharmacy Patient Care Center, Perryville, MD
Treatment
Options**
o Eat Plant Stanols / Sterols (additive to margarines, salad dressin, mayonnaise) and Fiber (Non-drug
Therapy –
include all
therapeutic
classes/agents
available and
preferences
per treatment
guidelines)
**See
Treatment
Options Table
o Gemfibrozile (Lopid) o Clofibrate (d/c) o Cholestyramine o Colestipol (Colestid) o Colesevelam (Welchol) o Lovastatin + Niacin (Advicor) o Atorvastatin + Amlodipine (Caduet) o Pravastatin + ASA (Pravigard Pac) o Simvastatin + Ezetimibe (Vytorin) o Pharmacotherapy Presentation – Pharmaceutical Care Rotation University of Maryland School of Pharmacy Happy Harry’s Pharmacy Patient Care Center, Perryville, MD Pharmacological Treatment Options for Dyslipidemia
KHOI NGUYEN LAM

Statins Fibric
Lovastation (Mevacor, Altocor/Altoprave) Availability
Generic (Brand)
Cerivastatin (Baycol)***d/c 2001 Rosuvastatin (Crestor) Fluvastatin (Lescol) Pravastatin (Pravachol) Mechanism
• Analogue for cholesterol precursor (HMG CoA) of Action
• Binds to HMG CoA Reductase and destroys it • By lowering LDL, increase LDL receptor on Liver • Breaks down and remove chylomicron, VLDL EFFICACY
(Indication/Use,
Clinical Data
• Antiproliferation effects on smooth muscle cells Support)
o Dyspepsia 20%, ab pain 10%, diarrhea 7%, (Major Drug
o Constipation, flatulence, dyspepsia, ab pain Interactions,
o Similar to Placebo, abnormal LFT (FENO) Pre-cautions,
o Hepatitis, cholestasis, jaundice, cirrhosis, hep indications,
o Antidiabetic agents, hypoglycemia, incr insulin Adverse Effects,
o Infection, rhinitis, sinusitis, steve-johnson Pregnancy Risk
o GEM, Bile Acid Seq, take two hours apart Category)
o 3A4 substrate (amiodarone, barbiturates, St. John’s Wort, phenytoin, anti-retroviral protease o Ezetimibe, (w/GEM, ?, cause cholelithiasis) o 2C9 substrate for Fluvastatin (amiodarone, fluoxetine, zafirlukast, STI-571”Imatinib”, Pharmacotherapy Presentation – Pharmaceutical Care Rotation University of Maryland School of Pharmacy Happy Harry’s Pharmacy Patient Care Center, Perryville, MD Statins Fibric
o Digoxin toxicity (80mg/QD strength) o Erythomycin, Clarithromycin (Myopathy) o Exenatide (AUC, Cmax decr, clinical relevance o Fibric Acid (Myopathy) o Other Statins o Oral Contraceptives (Lipitor, Crestor) o Glitazone (Lipitor) o Repaglinide “Prandin” (Zocor) incr Prandin SE o Warfarin (Lovastatin, Fluvastatin, Crestor, o EtOH o Asians (Crestor) – 2X plasma o DM (renal dx) o Elderly o Renal defficient o Hepatic deficient o Alcoholism o Hepatic Disease o Manitol hypersensitivity (Baycol) Dosage &
Administration
(Include renal
and/or hepatic
adjustments)
Monitoring
• Toxicity :: CPK (creatine phoshokinase, • Tell your dr other medications you’re taking Education
• Cause blurred vision, dizziness (careful Lovastatin 40mg = $62.90 Pravachol 40mg = $147.03 Crestor 40mg = $116.57 Zocor Simvastatin References
Pharmacotherapy Presentation – Pharmaceutical Care Rotation University of Maryland School of Pharmacy Happy Harry’s Pharmacy Patient Care Center, Perryville, MD Pharmacological Treatment Options for Dyslipidemia
KHOI NGUYEN LAM
2-azetidinone compound
Nicotinic Acid
Bile Acid Sequesterates
Availability
Generic (Brand)
Mechanism
of Action
EFFICACY
(Indication/Use,
Clinical Data
Support)
• Not absorbed, safer toxicity profile (Major Drug
Interactions,
Pre-cautions,
indications,
Adverse Effects,
Pregnancy Risk
Category)
Dosage &
Administration
Pharmacotherapy Presentation – Pharmaceutical Care Rotation University of Maryland School of Pharmacy Happy Harry’s Pharmacy Patient Care Center, Perryville, MD 2-azetidinone compound
Nicotinic Acid
Bile Acid Sequesterates

Monitoring

(Efficacy and
Toxicity
Parameters)
• Take ezetimibe >2 hrs before or 4 Education
References
Pharmacotherapy Presentation – Pharmaceutical Care Rotation University of Maryland School of Pharmacy Happy Harry’s Pharmacy Patient Care Center, Perryville, MD Table B1. Estimate of 10-Year Risk for Men (Framingham Point Scores)
Total
Cholesterol

Age 20-39
Age 40-49
Age 50-59
Age 60-69
Age 70-79
Age 20-39
Age 40-49
Age 50-59
Age 60-69
Age 70-79
Nonsmoker
HDL (mg/dL)
Systolic BP (mmHg)
If Untreated
If Treated
Point Total
10-Year Risk %
Table B2. Estimate of 10-Year Risk for Women (Framingham Point Scores)
Total
Cholesterol

Age 20-39
Age 40-49
Age 50-59
Age 60-69
Age 70-79
Age 20-39
Age 40-49
Age 50-59
Age 60-69
Age 70-79
Nonsmoker
HDL (mg/dL)
Systolic BP (mmHg)
If Untreated
If Treated
Point Total
10-Year Risk %
  • LDL Cholesterol: The Primary Target of Therapy
  • Risk Assessment: First Step in Risk Management
  • Method of risk assessment: counting major risk factors and estimating 10-year CHD risk
  • Role of other risk factors in risk assessment
  • The link between risk assessment and cost effectiveness
  • Primary Prevention With LDL-Lowering Therapy
  • Secondary Prevention With LDL-Lowering Therapy
  • LDL-Lowering Therapy in Three Risk Categories
  • Multiple (2+) risk factors and 10-year risk •20%
  • Therapeutic Lifestyle Changes in LDL-Lowering Therapy
  • Drug Therapy to Achieve LDL Cholesterol Goals
  • Secondary prevention: drug therapy for CHD and CHD risk equivalents
  • LDL-lowering drug therapy for primary prevention
  • Benefit Beyond LDL Lowering: The Metabolic Syndrome as a Secondary Target of Therapy
  • Management of underlying causes of the metabolic syndrome
  • Specific Treatment of Lipid and Non-Lipid Risk Factors
  • Management of Specific Dyslipidemias
  • Special Considerations for Different Population Groups
  • Adherence to LDL-Lowering Therapy
  • Shared Features of ATP III and ATP II
  • Estimating 10-Year Risk for Men and Women
  • Source: http://www.abcforyourhealth.org/Pharmacotherapy/Dyslipidemia.pdf

    graytsky.com

    Since beginning her research into DNA markers for HOD and other Weimaraner inherited diseases, Dr. Noa Saffra has responded to numerous questions from Weimaraner Breeders. Noa would like to share with the membership the most often asked questions and her replies. Frequently Asked Questions About HOD By Noa Saffra DVM, PhD is a systemic disease that affects young include: depre

    Verslag sts 28-01-2012

    Plaats: Zaal ‘De Bokkerijder, Kaulillerdorp 38, 3950 Kaulille. Agendapunten: - Evaluatie zangwedstrijden waaraan wij deelnamen. - Uitreiking Belgische ligabeker 2011/2012. - Kalender samenstellen voor 2012-2013. - Verwelkoming van Wout van Gils, ons allen bekend van zijn “kanariehomepage” gevolgd door een uiteenzetting over de kweek in zijn algemeenheid. - Wat

    Copyright © 2010-2014 Drugstore Pdf Search